By Professor Matthew Gwyn Law

Journal articles

Brew BJ; Tisch S; Law MG, 2003, 'Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy', AIDS, 17, pp. 1094 - 1096

Birch C; Middleton T; Hales GP; Cooper DA; Law MG; Crowe S; Hoy JF; Emery S, 2003, 'Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing', Journal of Acquired Immune Deficiency Syndrome, 32, pp. 57 - 61

Law MG; Dore GJ; Bath N; Thompson S; Crofts N; Dolan K; Giles W; Gow P; Kaldor JM; Loveday S; Powell E; Spencer J; Wodak AD, 2003, 'Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001', International Journal of Epidemiology, 32, pp. 717 - 724

Law MG; Friss-Moller N; Weber R; Reiss P; Thiebaut R; Kirk O; d Arminio Monforte A; Pradier C; Morfeldt L; Calvo G; El-Sadr W; De Wit S; Sabin C; Lundgren JD, 2003, 'Modelling the three-year risk of myocardial infarction among participants in the D:A:D study.', HIV Medicine, 4, pp. 1 - 10

Dore GJ; Freeman A; Law MG; Kaldor JM, 2003, 'Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings', Antiviral Therapy, 8, pp. 365 - 372

Freeman A; Law MG; Kaldor JM; Dore GJ, 2003, 'Predicting progression to cirrhosis in chronic hepatitis C virus infection', Journal of Viral Hepatitis, 10, pp. 285 - 293

Law MG; Emery S, 2003, 'Selective exclusion of treatment arms in multi-arm randomized clinical trials', Statistics in Medicine, 22, pp. 19 - 30

Tisch S; Brake H; Law MG; Cole IE; Darveniza P, 2003, 'Spasmodic dysphonia: clinical features and effects of botulinum toxintherapy in 169 patients - an Australian experience', Journal of Clinical Neuroscience, 10, pp. 434 - 438

Mallon PW; Wand HC; Law MG; Miller JM; Cooper DA; Carr AD, 2003, 'Strong association between buffalo hump and high serum insulin concentrations in HIV-infected individuals', Antiviral Therapy, 8, pp. L61 - L61

Murray JM; Law MG; Gao Z; Kaldor JM, 2003, 'The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users', International Journal of Epidemiology, 32, pp. 708 - 714, http://ije.oxfordjournals.org/content/32/5/708.abstract

Freeman A; Pan Y; Harvey CE; Post JJ; Law MG; White PA; Rawlinson WD; Lloyd AR; Marinos G; Ffrench R, 2003, 'The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection', Journal of Hepatology, 38, pp. 349 - 356

Smith DG; Carr AD; Law MG; Martin A; Hoy JF; Hudson J; Cooper DA, 2003, 'Thymidine analogue withdrawal for patients on protease sparing therapy improves lipoatrophy but compromises antivrial control:the PIILR extension study', AIDS, 16, pp. 2489 - 2491, http://journals.lww.com/aidsonline/fulltext/2002/12060/thymidine_analogue_withdrawal_for_lipoatrophic.20.aspx

Collins S; Boyd A; Lee JS; Lewis V; Fletcher A; McLean CA; Law M; Kaldor J; Smith MJ; Masters CL, 2002, 'Creutzfeldt-Jakob disease in Australia 1970-1999', Neurology, 59, pp. 1365 - 1371, http://dx.doi.org/10.1212/01.WNL.0000031793.11602.8C

Kirk O; Pedersen C; Law M; Gulick RM; Moyle G; Montaner J; Eron JJ; Phillips AN; Lundgren JD, 2002, 'Analysis of virological efficacy in trials of antiretroviral regimens: Drawbacks of not including viral load measurements after premature discontinuation of therapy', Antiviral Therapy, 7, pp. 271 - 281

Emery S; Birch C; Crowe S; Hoy J; Workman C; Kelleher T; McKenna P; Cooper D; Lincoln D; Hales G; Law M, 2002, 'CREST - A randomised comparison of two resistance test platforms: genotype and genotype plus VirtualPhenotype (TM): interim results', ANTIVIRAL THERAPY, 7, pp. S152 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000177401300141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Andersson R; Antunes F; Babiker AG; Breckenridge A; Brosgart C; Clezy KR; Cooper DA; Coakley D; Dally LG; Darbyshire JH; Floridia M; Fry J; Gatell J; Gazzard B; Goebel F; Goudsmit J; Hoy JF; Johnson MA; Hooker M; Kosmides J; Law MG; Mathiesen L; Reiss P; Soriano V; Vella S; Weverling GJ; Wit F; Withnall R, 2002, 'A randomised placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial', HIV Medicine, 3, pp. 229 - 238

Miller J; Brown DA; Amin J; Kent-Hughes J; Law MG; Cooper DA; Carr AD, 2002, 'A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia', AIDS, 16, pp. 2195 - 2200

Carr AD; Workman C; Smith DE; Hoy JF; Hudson J; Doong N; Martin A; Amin J; Freund J; Law MG; Cooper DA, 2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy', JAMA - Journal of the American Medical Association, 288, pp. 207 - 215

Lewin S; Ribeiro RM; Kaufmann GR; Smith DE; Zaunders J; Law MG; Solomon A; Cameron P; Cooper DA; Perelson AS, 2002, 'Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection', Journal of Immunology, 169, pp. 4657 - 4666

McDonald AM; Dore GJ; Grulich AE; Law MG; Prestage G; Smith DE, 2002, 'Epidemiological and social research finds at the 14th International AIDS Conference', Australian HIV Surveillance Report, 18, pp. 1 - 8

Li Y; Law MG; McDonald AM; Kaldor JM; Grulich AE, 2002, 'Estimation of risk of cancers before occurrence of acquired immunodeficiency syndrome in persons infected with human immunodeficiency virus', American Journal of Epidemiology, 155, pp. 153 - 158

Knox J; Tabrizi S; Miller P; Petoumenos K; Law MG; Chen S; Garland S, 2002, 'Evaluation of self-collected samples in contrast to practitioner collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas', Sexually Transmitted Diseases, 29, pp. 647 - 654

Carr AD; Workman C; Smith DE; Hoy JF; Doong N; Amin J; Law MG; Cooper DA, 2002, 'For the MITOX investigators: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial', Journal of the American Medical Association, 288, pp. 207 - 215

Ashton LJ; Stewart GJ; Biti RA; Law MG; Cooper DA; Kaldor JM, 2002, 'Heterozygosity for CCR5-∆32 but not CCR2b-64l protects against certain intracellular pathogens', HIV Medicine, 3, pp. 91 - 96

Dore GJ; Freeman A; Law MG; Kaldor JM, 2002, 'Is severe liver disease a common outcome for people with chronic hepatitis C?', Journal of Gastroenterology and Hepatology, 17, pp. 423 - 430

Law MG; Prestage G; Grulich AE; Van De Ven PG; Kippax SC, 2002, 'Modelling HIV incidence in gay men: increased treatment, unsafe sex and sexually transmissible infections', AIDS, 16, pp. 499 - 501

Jin F; Prestage G; Law MG; Kippax SC; Van De Ven PG; Rawstorne PR; Kaldor JM; Grulich AE, 2002, 'Predictors of recent HIV testing in homosexual men in Australia', HIV Medicine, 3, pp. 271 - 276

French MA; Amin J; Roth N; Law MG; Emery S; Drummond F, 2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185

Baker D; Law MG; Petoumenos K; Smith DE; Anderson JA; Roth N; Mallal SA, 2002, 'Rates of combination antiretroviral treatment change in Australia, 1997-2000', HIV Medicine, 3, pp. 28 - 36

Carr AD; Law MG; Baker D; Petoumenos K; Smith D; Anderson JA; Roth N; Mallal SS, 2002, 'Rates of combination antiretroviral treatment change in Australia', HIV Medicine, 3, pp. 28 - 36

Grulich AE; Li Y; McDonald AM; Correll PK; Law MG; Kaldor JM, 2002, 'Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis', AIDS, 16, pp. 1155 - 1161

Smith DE; Carr AD; Law MG; Hudson J; Hoy JF; Cooper DA, 2002, 'Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study', AIDS, 16, pp. 2489 - 2491

Law MG; Dore GJ; Kaldor JM, 2001, 'Projecting severe sequelae of injection-related hepatitis C virus epidemic in UK by SM Bird, DJ Goldberg and SJ Hutchinson', Journal of Epidemiology and Biostatistics, 6, pp. 279 - 281, http://dx.doi.org/10.1080/135952201317080689

Grulich AE; Law MG, 2001, 'Long-term high-dose acyclovir and aids- related non-hodgkins lymphoma [2]', Clinical Infectious Diseases, 32, pp. 989 - 990, http://dx.doi.org/10.1086/319359

Babiker AG; Darbyshire JH; Cooper DA; Hooker MH; Withnall R; Yeni P; Angarano G; Antunes F; Churchill D; Conway B; Flepp M; Lelekis M; Gatell J; Girard PM; Hemmer R; Lundgren J; Mijch A; Mulcahy F; Ristola M; Salzberger B; Sandström E; Staszewski S; Weber J; De Wit S; Aboulker JP; Emery S; Floridia M; Gartland M; Manion D; Popescu M; Schnittman S; Stek M; Verbiest W; Flandre P; Law M; Schade-Brittinger C; Walker S; Bucciardini R; Boukli N; Carey D; Gargalianos P; Mollerup D; Brun-Vezinet F; Loveday C; Seligmann M, 2001, 'An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the initio trial', Controlled Clinical Trials, 22, pp. 160 - 175, http://dx.doi.org/10.1016/S0197-2456(00)00123-9

Smith DE; Hales GP; Roth N; Law MG; Ray J; Druett J; Mitchell J; Mills G; Doong N; Franklin R, 2001, 'A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir¿SGC and stavudine in treatment¿experienced HIV-1 infected patients.', HIV Clinical Trials, 2, pp. 97 - 107

Law MG; Lynskey MT; Ross JE; Hall WD, 2001, 'Back-projection estimates of the number of dependent herion users in Australia', Addiction, pp. 433 - 443

Middleton T; Smith DE; Larder BA; Law MG; Birch C, 2001, 'Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.', HIV Clinical Trials, 2, pp. 445 - 452

Grulich AE; Li Y; McDonald AM; Correll PK; Law MG; Kaldor JM, 2001, 'Decreasing rates of Kaposi¿s sarcoma and non-Hodgkin¿s lymphoma in the era of potent combination antiretroviral therapy', AIDS, 15, pp. 629 - 633

Freeman A; Dore GJ; Law MG; Thorpe M; Von Overbeck J; Lloyd AR; Marinos G; Kaldor JM, 2001, 'Estimating progression to cirrhosis in chronic hepatitis C virus infection.', Hepatology, pp. 809 - 816

Carr AD; Hudson J; Chuah J; Law MG; Mallal SA; Hoy JF; Doong N; French MA; Smith DE; Cooper DA, 2001, 'HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study', AIDS, 15, pp. 1811 - 1822

Miller P; Law MG; Torzillo P; Kaldor JM, 2001, 'Incident sexually transmitted infections and their risk factors in an Aboriginal community in Australia: a population based cohort study.', Sexually Transmitted Infections, pp. 21 - 25

Law MG; Prestage G; Grulich AE; Van De Ven PG; Kippax SC, 2001, 'Modelling the effect of combination antiretroviral treatments on HIV incidence', AIDS, 15, pp. 1287 - 1294

Shiell A; Law MG, 2001, 'The cost of hepatitis C and the cost ¿ effectiveness of its prevention.', Health Policy, pp. 121 - 131

Carr AD; Baker D; Petoumenos K; Law MG; Smith D; Roth N; Anderson JA; Mallal SS, 2001, 'Time trends in antiretroviral treatment use in Australia', Venereology - the Interdisciplinary International Journal of Sexual Health, 14, pp. 162 - 168

Correll PK; Law MG; Seed CR; Gust A; Buring M; Dax E; Keller AJ; Kaldor JM, 2001, 'Variant Cruetzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies', Vox Sanguinis, pp. 6 - 11

Hales G; Roth N; Law M; Smith D, 2000, 'Enhancing saquinavir levels by utilising novel antiretrovirals as cytochrome P450 inhibitors', AIDS, 14, pp. S99 - S100, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165192300335&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Law MG, 2000, 'Rates of change of combination antiretroviral treatments in Australia, 1997-2000', AIDS, 14, pp. S136 - S137, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000165192300463&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Freeman AJ; Dore GJ; Law MG; Thorpe M; Von Overbeck J; Lloyd AR; Marinos G; Kaldor JM, 2000, 'The natural history of chronic hepatitis C: A systematic review', HEPATOLOGY, 32, pp. 422A - 422A, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000089622401038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carr AD; Chuah J; Hudson J; French MA; Hoy JF; Law MG; Sayer D; Emery S; Cooper DA; On BOTC, 2000, 'A randomised, open-label comparison of three highly active antiretroviral therapy regimes including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study', AIDS, 14, pp. 1171 - 1180

Back to profile page